"That’s because nearly half of biotechnology investment money last year was raised through debt financing deals by larger mature companies, which used it to buy back their own shares, boosting earnings and share prices....
--more--"
Related: VenCap Vroom-Vroom
Yeah, you are the big loser again, Americans.
